These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 2107593

  • 1. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
    Lijnen HR, Dewerchin M, De Cock F, Collen D.
    Thromb Res; 1990 Feb 01; 57(3):333-42. PubMed ID: 2107593
    [Abstract] [Full Text] [Related]

  • 2. Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin.
    Dewerchin M, Lijnen HR, Van Hoef B, De Cock F, Collen D.
    Eur J Biochem; 1989 Oct 20; 185(1):141-9. PubMed ID: 2530085
    [Abstract] [Full Text] [Related]

  • 3. Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase.
    Holvoet P, Laroche Y, Lijnen HR, Van Cauwenberge R, Demarsin E, Brouwers E, Matthyssens G, Collen D.
    J Biol Chem; 1991 Oct 15; 266(29):19717-24. PubMed ID: 1918077
    [Abstract] [Full Text] [Related]

  • 4. Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
    Holvoet P, Laroche Y, Lijnen HR, Van Hoef B, Brouwers E, De Cock F, Lauwereys M, Gansemans Y, Collen D.
    Eur J Biochem; 1992 Dec 15; 210(3):945-52. PubMed ID: 1483477
    [Abstract] [Full Text] [Related]

  • 5. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M, Vandamme AM, Holvoet P, De Cock F, Lemmens G, Lijnen HR, Stassen JM, Collen D.
    Thromb Haemost; 1992 Aug 03; 68(2):170-9. PubMed ID: 1412163
    [Abstract] [Full Text] [Related]

  • 6. Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Vandamme AM, Dewerchin M, Lijnen HR, Bernar H, Bulens F, Nelles L, Collen D.
    Eur J Biochem; 1992 Apr 01; 205(1):139-46. PubMed ID: 1313361
    [Abstract] [Full Text] [Related]

  • 7. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.
    Declerck PJ, Lijnen HR, Verstreken M, Moreau H, Collen D.
    Blood; 1990 May 01; 75(9):1794-800. PubMed ID: 1691934
    [Abstract] [Full Text] [Related]

  • 8. The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro.
    Lijnen HR, Van Hoef B, De Cock F, Collen D.
    Blood; 1989 May 15; 73(7):1864-72. PubMed ID: 2713507
    [Abstract] [Full Text] [Related]

  • 9. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.
    Jiao J, Yu M, Ru B.
    Biochim Biophys Acta; 2001 Apr 07; 1546(2):399-405. PubMed ID: 11295444
    [Abstract] [Full Text] [Related]

  • 10. Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.
    Holvoet P, Dewerchin M, Stassen JM, Lijnen HR, Tollenaere T, Gaffney PJ, Collen D.
    Circulation; 1993 Mar 07; 87(3):1007-16. PubMed ID: 8443877
    [Abstract] [Full Text] [Related]

  • 11. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.
    Nelles L, Lijnen HR, Collen D, Holmes WE.
    J Biol Chem; 1987 Aug 05; 262(22):10855-62. PubMed ID: 2956260
    [Abstract] [Full Text] [Related]

  • 12. Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential.
    Lijnen HR, Wnendt S, Schneider J, Janocha E, Van Hoef B, Collen D, Steffens GJ.
    Eur J Biochem; 1995 Nov 15; 234(1):350-7. PubMed ID: 8529664
    [Abstract] [Full Text] [Related]

  • 13. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
    Collen D, Dewerchin M, Rapold HJ, Lijnen HR, Stassen JM.
    Circulation; 1990 Nov 15; 82(5):1744-53. PubMed ID: 2121385
    [Abstract] [Full Text] [Related]

  • 14. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
    Kurokawa T, Iwasa S, Kakinuma A, Stassen JM, Lijnen HR, Collen D.
    Thromb Haemost; 1991 Dec 02; 66(6):684-93. PubMed ID: 1796414
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala.
    Lijnen HR, Li XK, Nelles L, Hu MH, Collen D.
    Eur J Biochem; 1992 Apr 15; 205(2):701-9. PubMed ID: 1533368
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.